Clinical evaluation of botulinum toxin A in the management of temporomandibular myofascial pain

Stonehouse-Smith, Daniel; Begley, Anne; Dodd, Martin

doi:10.1016/j.bjoms.2019.11.010

Cited by 5 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Retrospective studies, such as that by Stonehouse-Smith et al [30], which included 100 patients with temporo-mandibular myofascial pain, found a pain reduction of 2.48 points on the VAS scale 16 weeks after the injection of BTA in doses of 100 units. No significant differences in pain reduction were seen in patients injected with doses of 200 units (20).…”

Section: Discussionmentioning

confidence: 99%

“…For example, Emberg et al [23] treated the masseter muscle alone, possibly limiting the observable effects, while the other studies reported the injection of at least one temporal muscle along with the masseter injection, with Lindern et al including the medial pterygoid [21] and Nixdorf et al the lateral pterygoid [22]. The total dose ranged from 50 units unilaterally to 300 units bilaterally [30]. In our trial, doses between 100 and 150 units bilaterally distributed to the masseter, temporal, and pterygoid muscles were used.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection

Montes-Carmona

González-Pérez

Infante-Cossio

2020

Toxins

View full text Add to dashboard Cite

Botulinum toxin type A (BTA) injection is considered an available alternative treatment for myofascial pain. However, its efficacy in treating masticatory myofascial pain syndrome (MMPS) remains unclear. The purpose of this study was to evaluate whether the BTA injection into the affected muscles would significantly reduce pain and improve function, and to assess its efficacy, safety, and therapeutic indications in a randomized, single-center clinical trial. Sixty patients with MMPS were randomized into three groups evenly to receive a single session injection of saline solution (SS group), lidocaine (LD group), and BTA (BTA group) in the masseter, temporal, and pterygoid muscles after an electromyographic study. Patients’ pain was classified as localized or referred according to the DC/TMD classification. Assessments were performed on pre-treatment, and subsequently, on days 7, 14, 28, 60, 90, and 180. A significant reduction in pain and improvement of mandibular movements was found in the BTA group compared to the SS and LD groups. The response lasted until day 180 and was more intense in patients with localized myalgia and focused myofascial pain than in referred remote pain. No significant adverse reactions were observed. A single BTA injection can be considered an effective treatment option in patients with localized MMPS by reducing pain and improving mandibular movements, which persisted up to 6 months.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection

Montes-Carmona

González-Pérez

Infante-Cossio

2020

Toxins

View full text Add to dashboard Cite

show abstract

“…Stonehouse‐Smith et al 31 recently published a similar retrospective review on the effectiveness of Botulinum A injections for the treatment of myofascial TMDs. Despite their cohort of patients mean starting level of pain being higher than in this review (7.54 out of 10 on a similar 11‐point NPRS scale), it is noteworthy that the mean level of improvement reported in our study (3.7) was greater than that reported by Stonehouse‐Smith (2.48).…”

Section: Discussionmentioning

confidence: 99%

Physiotherapy for the management of temporomandibular disorders: Findings from United Kingdom practice

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Consequently, it was originally applied for treating diseases associated with muscle hyperactivity, such as dystonia [2][3][4][5]. The toxin has also been used for diseases in the orofacial region, such as oromandibular dystonia [6][7][8][9][10][11][12], trigeminal neuralgia [13][14][15][16][17][18][19][20], temporomandibular disorders, and bruxism [21][22][23][24][25][26][27][28][29][30][31]. Furthermore, the botulinum neurotoxin has been proven to be effective for pain relief of different pain types, including chronic migraine, neuropathic pain, trigeminal neuralgia, and myofascial pain [32][33][34].…”

Section: Introductionmentioning

confidence: 99%

“…Temporomandibular disorders (TMDs) are a heterogeneous group of chronic pain conditions that affect the temporomandibular joint, masticatory muscles, and related structures. Despite the inconsistency of published data concerning the application of persistent myofascial pain with BoNT/A [25][26][27][28][29][30][31], shortcomings such as a small sample size and a lack of standardized management protocols have led to inconsistent results.…”

Section: Introductionmentioning

confidence: 99%

Effects of Botulinum Toxin Type A on Pain among Trigeminal Neuralgia, Myofascial Temporomandibular Disorders, and Oromandibular Dystonia

Yoshida

2021

Toxins

View full text Add to dashboard Cite

The differences in analgesic effects of botulinum toxin type A were compared in 28 patients with trigeminal neuralgia, 53 patients with myofascial temporomandibular disorders, and 89 patients with the jaw closing oromandibular dystonia. The patients were treated by injection of botulinum toxin type A into the masseter, temporalis, medial pterygoid, and other muscles based on the symptoms of each patient. The pain severity was evaluated using the visual analog scale, pain frequency, and pain scale of the oromandibular dystonia rating scale. Botulinum toxin injection was performed 1068 times in all patients without significant adverse effects. The visual analog, pain frequency, and pain scales at baseline were reduced (p < 0.001) after two, four, eight, and 12 weeks after the first botulinum toxin therapy and at the endpoint. The effects differed significantly (p < 0.001) among the groups (repeated-measures analysis of variance). The mean improvement (0%, no effect; 100%, complete recovery) at the endpoint was 86.8% for trigeminal neuralgia, 80.8% for myofascial pain, and 75.4% for oromandibular dystonia. Injection of the botulinum toxin can be a highly effective and safe method to treat trigeminal neuralgia, myofascial pain, and oromandibular dystonia.

show abstract

Clinical evaluation of botulinum toxin A in the management of temporomandibular myofascial pain

Cited by 5 publications

References 10 publications

Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection

Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection

Physiotherapy for the management of temporomandibular disorders: Findings from United Kingdom practice

Effects of Botulinum Toxin Type A on Pain among Trigeminal Neuralgia, Myofascial Temporomandibular Disorders, and Oromandibular Dystonia

Contact Info

Product

Resources

About